A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Conditions: Respiratory Syncytial Virus Infections Interventions: Biological: RSVPreF3 OA investigational vaccine; Biological: COVID-19 mRNA vaccine Sponsors: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials